格隆汇11月19日丨西点药业(301130.SZ)在投资者互动平台表示，公司现有已上市产品方面，公司拥有 成熟的抗流感药物复方氨酚烷胺胶囊，以及于2025年获得批准上市的抗病毒片临床上用于治疗上呼吸道 感染及流行性感冒。公司的在研项目"瑞香素对人类疾病小鼠模型干预效果的研究"子项目"瑞香素对小 鼠病毒性肺炎模型干预效果研究"中已获得了瑞香素在病毒性肺炎治疗中具有安全性和有效性的实验结 果，已获得《瑞香素在制备治疗病毒性肺炎的药物中的应用》发明专利。 ...

Core Viewpoint - The company has existing flu medication products and is developing new antiviral treatments, indicating a strong position in the respiratory infection market [2]. Product Overview - The company currently markets a mature flu medication, Compound Acetaminophen and Amantadine Capsules [2]. - An antiviral tablet is expected to receive approval for market launch in 2025, aimed at treating upper respiratory infections and influenza [2]. Research and Development - The company is conducting research on "Rui Xiang Su" for its effects on viral pneumonia in mouse models, showing safety and efficacy [2]. - A patent has been obtained for the application of "Rui Xiang Su" in the preparation of drugs for treating viral pneumonia [2]. - The company is the sole producer and seller of "Rui Xiang Su" capsules in China [2].

Group 1 - The company has not declared any cash dividends or bonus shares during the reporting period [3] - The company received several approvals from the National Medical Products Administration for its products, including sodium hyaluronate eye drops and antiviral tablets [5] - The company held its eighth board meeting on August 14, 2025, where various reports and proposals were approved [40][41] Group 2 - The company reported a total fundraising amount of RMB 455.53 million from its initial public offering, with a net amount of RMB 390.93 million after expenses [27][28] - The company has established a fundraising management system to ensure compliance with regulations and protect investor interests [30] - As of June 30, 2025, the company has used RMB 44.55 million of its excess fundraising to permanently supplement its working capital [33][35] Group 3 - The company plans to hold its first extraordinary general meeting of 2025 on September 2, 2025, to discuss various proposals [8][52] - The meeting will allow shareholders to vote both in person and online, ensuring accessibility for all stakeholders [9][10] - The company has made amendments to its internal management systems to enhance operational efficiency and compliance with legal requirements [7][50]

Core Points - The report summarizes the financial performance and operational status of Jilin Xidian Pharmaceutical Technology Development Co., Ltd. for the first half of 2025, highlighting a slight decrease in revenue but an increase in net profit [1][2]. Financial Performance - Operating revenue for the reporting period was CNY 128,311,809.27, a decrease of 0.51% compared to the same period last year [1]. - Net profit attributable to shareholders was CNY 24,944,585.08, reflecting a growth of 2.02% year-on-year [1]. - Net cash flow from operating activities increased by 3.49% to CNY 33,713,141.57 [1]. - Basic earnings per share rose by 7.77% to CNY 0.3261, while diluted earnings per share increased by 5.43% to CNY 0.3261 [1]. - The weighted average return on equity was 2.73%, up from 2.56% in the previous year [1]. Asset and Equity Status - Total assets at the end of the reporting period were CNY 1,055,706,506.89, a decrease of 0.65% from the previous year [1]. - Net assets attributable to shareholders increased by 0.56% to CNY 910,831,590.25 [1]. Shareholder Information - The largest shareholder, Zhang Jun, holds 25.66% of the shares, amounting to 19,627,034 shares [2]. - Other significant shareholders include Dingdian Investment Management (7.86%) and Zhuhai Hengqin Yanhe Health Technology (4.83%) [2][3]. - The report indicates that there are no changes in the controlling shareholder or actual controller during the reporting period [4]. Important Events - The company received approval for several drug applications, including sodium hyaluronate eye drops and antiviral tablets, which may enhance its product portfolio and market position [6].

Core Viewpoint - The company, Jilin Xidian Pharmaceutical Technology Development Co., Ltd., has released its annual report for 2024, highlighting its financial performance, business operations, and future development plans. The report indicates a focus on the research, production, and sales of chemical raw materials and formulations, particularly in the fields of iron supplementation and psychiatric medications [1][5]. Company Overview - The company primarily engages in the research, production, and sales of chemical raw materials and formulations, with a strong emphasis on iron supplementation, treatment of circulatory disorders, and psychiatric medications [5]. - As of the end of the reporting period, the company holds 25 registered formulation varieties (32 specifications) and 16 registered raw material drug approvals, focusing on anti-anemia, circulatory disorder treatments, and psychiatric medications [5]. Financial Highlights - The company has received a standard unqualified audit opinion from Rongcheng Accounting Firm for the financial report of the reporting period [3]. - The board of directors approved a profit distribution plan, proposing a cash dividend of 2.60 yuan per 10 shares (including tax), with no stock bonus or capital reserve transfer [4][9]. Shareholder Information - The company has no preferred shareholders and has disclosed the shareholding structure, including the top 10 shareholders [7][8]. Recent Developments - The company has received several approvals for new drug applications, including sodium hyaluronate eye drops and other formulations, indicating ongoing product development and regulatory compliance [8][65]. - The company has also obtained a patent for the application of rhizoma smilacis in preparing drugs for treating lymphatic reflux disorders [10][67]. Governance and Compliance - The company’s board and supervisory committee have ensured that the annual report and its summary are accurate and complete, with no misleading statements or omissions [11][18]. - The company has appointed Rongcheng Accounting Firm as its auditor for the year 2025, following a thorough review of the firm’s qualifications and capabilities [42][56].

Group 1 - The company has received the approval notice for the supplement application of its antiviral tablet from the National Medical Products Administration [1] - The antiviral tablet is classified as a traditional Chinese medicine and is produced by the company, with the production site and quality standards remaining unchanged [1][2] - The approval of this product is expected to enhance the company's product line and market competitiveness, positively impacting future performance [3] Group 2 - The antiviral tablet contains ingredients such as Ban Lan Gen, Shi Gao, Di Huang, and others, and is primarily used for treating wind-heat colds, upper respiratory infections, and influenza [2] - The approval process followed the relevant regulations under the Drug Administration Law of the People's Republic of China, confirming compliance with registration requirements [1]